Depixus to showcase unique single molecule technology solving the hit-to-lead challenge in RNA-targeted drug discovery at upcoming Discovery on Target Conference
20th September 2023
PARIS–(BUSINESS WIRE)–Dr Gordon Hamilton, President & CEO of Depixus SAS, will be showcasing the company’s pioneering approach to transform RNA…
Read More
WEBINAR – Tuesday 12th April, 5pm CEST/11am EDT
Depixus® is developing its MAGNA™ platform to unlock dramatic new insights into the largely unmined richness of the “dynamic genome” by detecting changes beyond the four-base sequences of DNA and RNA, paving the way to revolutionise molecular diagnostics and drug development. Dr Jimmy Ouellet, Chief Scientist will introduce the MAGNA™ platform, and through examples, illustrate […]
Read More
Novel technology expected to greatly advance the burgeoning field of dynamic genomics
18th March 2021
Wide range of possible translational and clinical applications, including virology and epigenetic biomarker discovery for liquid biopsy tests
Read More